RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing
RETAIN
Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing Through Active Patients Sharing Experiences and the Provision of Information About Infections -an electroNic-health Application
1 other identifier
interventional
40
1 country
1
Brief Summary
The purpose of this research study is to:
- 1.assess how well individuals entering medication assisted treatment like the RETAIN e-health application as measured by their feedback on the intervention.
- 2.test the impact of RETAIN on knowledge about medication-assisted treatment(MAT).
- 3.assess treatment retention rates in patients completing the RETAIN intervention.
- 4.test the impact of RETAIN on knowledge about HCV/HIV
- 5.test the impact of RETAIN on interest in being tested for HCV/HIV
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2017
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 8, 2017
CompletedFirst Submitted
Initial submission to the registry
January 10, 2018
CompletedFirst Posted
Study publicly available on registry
January 26, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 6, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
September 6, 2018
CompletedApril 10, 2019
April 1, 2019
10 months
January 10, 2018
April 9, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
treatment retention status after 3 months
To compare with retention rates for the overall MAT clinics and use in sample size calculations for potential follow-on trial
3 months
Secondary Outcomes (4)
treatment retention status after 6 months
6 months
MAT Knowledge Assessment
Pre and Post Tests in E-Health App Day 1
The Injection-Related Infection and Treatment Survey (I-RITS)
Pre and Post Tests in E-Health App Day 1
Feedback on the RETAIN e-health application
Day 1
Study Arms (1)
RETAIN
EXPERIMENTALParticipants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
Interventions
RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize "scalability" - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention.
Eligibility Criteria
You may qualify if:
- At least 18 years of age
- Starting MAT with methadone or suboxone or in MAT for less than 2 weeks;
You may not qualify if:
- Does not sign the "short form" consent form
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Cincinnati Addiction Sciences Division
Cincinnati, Ohio, 45229, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Theresa Winhusen, PhD
University of Cincinnati
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 10, 2018
First Posted
January 26, 2018
Study Start
November 8, 2017
Primary Completion
September 6, 2018
Study Completion
September 6, 2018
Last Updated
April 10, 2019
Record last verified: 2019-04